Boston Scientific (NYSE: BSX, ISIN US10117L1017) opened trading on September 14, 2026, following a 0.28% decline to close at USD 42.98 on the NYSE on September 11, 2026. After-hours activity subsequently pushed the share price higher to USD 43.21, suggesting modest stabilization as the stock remained within its established 52-week range and above recent lows. The initial dip was primarily attributed to earlier market pressure linked to a cyberattack that disrupted operations, rather than a broad selloff in the US healthcare sector where major indices posted only fractional moves. The operational disruption stems from a cyberattack disclosed on August 25, 2026, which temporarily interrupted manufacturing and shipping at the company's sterile cleanroom facility for heart catheter systems located in Marlborough, MA. In response to this incident, Boston Scientific withdrew and reset its financial guidance, a move that had weighed on shares earlier in the week. However, management emphasized that demand and device performance remained intact, with the guidance adjustment reflecting only the near-term impact of the disruption rather than a change in underlying business trends. As of September 14, 2026, there are no scheduled quarterly earnings releases or annual meetings for Boston Scientific, leaving investor focus centered on the company's recovery trajectory from the cyberattack. Market expectations remain tied to management's comments regarding the pace of manufacturing and logistics recovery following the August 25 incident. While broader macro factors such as updates on healthcare policy or reimbursement rates continue to influence the sector, stock-specific news regarding the resolution of the operational disruption remains the primary driver for Boston Scientific's share performance into the open.